BACKGROUND:Flavopiridol is a protein-bound, cytotoxic, cyclin dependent kinase inhibitor. A phase II trial of flavopiridol followed by ara-C and mitoxantrone with flavopiridol given by 1-h bolus for adults with newly-diagnosed, poor-risk acute myelogenous leukemia yielded 67% complete remission with median disease-free survival of 13.6 months. DESIGN AND METHODS: We compared bolus flavopiridol (50 mg/m(2)/day, Arm A) versus 'hybrid' flavopiridol (30 mg/m(2) over 30 min followed by 40 mg/m(2) over 4 h, Arm B) followed by ara-C and mitoxantrone in 78 patients (39 per arm) with newly diagnosed, poor-risk acute myelogenous leukemia. To mitigate imbalance, patients were stratified by presence or absence of secondary leukemia and therapy for antecedent disorder. RESULTS:Death at or before Day 60 occurred in 8% of patients per arm. Complete remission plus complete remission with incomplete recovery was 68% (Arm A, 62%; Arm B, 74%) overall, and 65% or over in both arms for patients with secondary leukemia and leukemia with adverse genetics. In Arm A 91% and in Arm B 86% of patients received chemotherapy and/or allogeneic transplantation in complete remission. Median overall survival for all remission patients has not been reached for either arm, with median disease free survival of 13.6 months for Arm A and of 12.0 months for Arm B. CONCLUSIONS: Both flavopiridol schedules produce comparably encouraging results in adults with poor-risk acute myelogenous leukemia. Given the greater ease of bolus administration, we are conducting a randomized phase II study of bolus flavopiridol followed by ara-c and mitoxantrone versus conventional induction therapy for patients aged 70 years and under with intermediate or poor-risk acute myelogenous leukemia. This study is registered at www.clinicaltrials.gov as #NCT 00407966.
RCT Entities:
BACKGROUND:Flavopiridol is a protein-bound, cytotoxic, cyclin dependent kinase inhibitor. A phase II trial of flavopiridol followed by ara-C and mitoxantrone with flavopiridol given by 1-h bolus for adults with newly-diagnosed, poor-risk acute myelogenous leukemia yielded 67% complete remission with median disease-free survival of 13.6 months. DESIGN AND METHODS: We compared bolus flavopiridol (50 mg/m(2)/day, Arm A) versus 'hybrid' flavopiridol (30 mg/m(2) over 30 min followed by 40 mg/m(2) over 4 h, Arm B) followed by ara-C and mitoxantrone in 78 patients (39 per arm) with newly diagnosed, poor-risk acute myelogenous leukemia. To mitigate imbalance, patients were stratified by presence or absence of secondary leukemia and therapy for antecedent disorder. RESULTS: Death at or before Day 60 occurred in 8% of patients per arm. Complete remission plus complete remission with incomplete recovery was 68% (Arm A, 62%; Arm B, 74%) overall, and 65% or over in both arms for patients with secondary leukemia and leukemia with adverse genetics. In Arm A 91% and in Arm B 86% of patients received chemotherapy and/or allogeneic transplantation in complete remission. Median overall survival for all remission patients has not been reached for either arm, with median disease free survival of 13.6 months for Arm A and of 12.0 months for Arm B. CONCLUSIONS: Both flavopiridol schedules produce comparably encouraging results in adults with poor-risk acute myelogenous leukemia. Given the greater ease of bolus administration, we are conducting a randomized phase II study of bolus flavopiridol followed by ara-c and mitoxantrone versus conventional induction therapy for patients aged 70 years and under with intermediate or poor-risk acute myelogenous leukemia. This study is registered at www.clinicaltrials.gov as #NCT 00407966.
Authors: Judith E Karp; B Douglas Smith; Linda S Resar; Jacqueline M Greer; Amanda Blackford; Ming Zhao; Dwella Moton-Nelson; Katrina Alino; Mark J Levis; Steven D Gore; Biju Joseph; Hetty Carraway; Michael A McDevitt; Lorena Bagain; Karen Mackey; Janet Briel; L Austin Doyle; John J Wright; Michelle A Rudek Journal: Blood Date: 2011-01-14 Impact factor: 22.113
Authors: Chunrong Yu; Mohamed Rahmani; Yun Dai; Daniel Conrad; Geoffrey Krystal; Paul Dent; Steven Grant Journal: Cancer Res Date: 2003-04-15 Impact factor: 12.701
Authors: Judith E Karp; Douglas D Ross; Weidong Yang; Michael L Tidwell; Yuetong Wei; Jacqueline Greer; Dean L Mann; Takeo Nakanishi; John J Wright; A Dmitri Colevas Journal: Clin Cancer Res Date: 2003-01 Impact factor: 12.531
Authors: Antoinette R Tan; Donna Headlee; Richard Messmann; Edward A Sausville; Susan G Arbuck; Anthony J Murgo; Giovanni Melillo; Suoping Zhai; William D Figg; Sandra M Swain; Adrian M Senderowicz Journal: J Clin Oncol Date: 2002-10-01 Impact factor: 44.544
Authors: John C Byrd; Krzysztof Mrózek; Richard K Dodge; Andrew J Carroll; Colin G Edwards; Diane C Arthur; Mark J Pettenati; Shivanand R Patil; Kathleen W Rao; Michael S Watson; Prasad R K Koduru; Joseph O Moore; Richard M Stone; Robert J Mayer; Eric J Feldman; Frederick R Davey; Charles A Schiffer; Richard A Larson; Clara D Bloomfield Journal: Blood Date: 2002-08-01 Impact factor: 22.113
Authors: L T Lam; O K Pickeral; A C Peng; A Rosenwald; E M Hurt; J M Giltnane; L M Averett; H Zhao; R E Davis; M Sathyamoorthy; L M Wahl; E D Harris; J A Mikovits; A P Monks; M G Hollingshead; E A Sausville; L M Staudt Journal: Genome Biol Date: 2001-09-13 Impact factor: 13.583
Authors: D R Haudenschild; A K Carlson; D L Zignego; J H N Yik; J K Hilmer; R K June Journal: Osteoarthritis Cartilage Date: 2018-12-18 Impact factor: 6.576
Authors: Prithviraj Bose; Edward B Perkins; Connie Honeycut; Martha D Wellons; Tammy Stefan; James W Jacobberger; Emmanouil Kontopodis; Jan H Beumer; Merrill J Egorin; Chiyo K Imamura; W Douglas Figg; Judith E Karp; Omer N Koc; Brenda W Cooper; Selina M Luger; A Dimitrios Colevas; John D Roberts; Steven Grant Journal: Cancer Chemother Pharmacol Date: 2012-02-15 Impact factor: 3.333
Authors: Joshua F Zeidner; Matthew C Foster; Amanda L Blackford; Mark R Litzow; Lawrence E Morris; Stephen A Strickland; Jeffrey E Lancet; Prithviraj Bose; M Yair Levy; Raoul Tibes; Ivana Gojo; Christopher D Gocke; Gary L Rosner; Richard F Little; John J Wright; L Austin Doyle; B Douglas Smith; Judith E Karp Journal: Haematologica Date: 2015-05-28 Impact factor: 9.941
Authors: Joshua F Zeidner; Matthew C Foster; Amanda L Blackford; Mark R Litzow; Lawrence E Morris; Stephen A Strickland; Jeffrey E Lancet; Prithviraj Bose; M Yair Levy; Raoul Tibes; Ivana Gojo; Christopher D Gocke; Gary L Rosner; Richard F Little; John J Wright; L Austin Doyle; B Douglas Smith; Judith E Karp Journal: Leuk Res Date: 2018-08-10 Impact factor: 3.156
Authors: Kelly J Norsworthy; Amy E DeZern; Hua-Ling Tsai; Wesley A Hand; Ravi Varadhan; Steven D Gore; Ivana Gojo; Keith Pratz; Hetty E Carraway; Margaret Showel; Michael A McDevitt; Douglas Gladstone; Gabriel Ghiaur; Gabrielle Prince; Amy H Seung; Dina Benani; Mark J Levis; Judith E Karp; B Douglas Smith Journal: Leuk Res Date: 2017-08-30 Impact factor: 3.156
Authors: T K Albert; C Rigault; J Eickhoff; K Baumgart; C Antrecht; B Klebl; G Mittler; M Meisterernst Journal: Br J Pharmacol Date: 2014-01 Impact factor: 8.739
Authors: Beata Holkova; Maciej Kmieciak; E Brent Perkins; Prithviraj Bose; Rachid C Baz; G David Roodman; Robert K Stuart; Viswanathan Ramakrishnan; Wen Wan; Cody J Peer; Jana Dawson; Loveleen Kang; Connie Honeycutt; Mary Beth Tombes; Ellen Shrader; Caryn Weir-Wiggins; Martha Wellons; Heidi Sankala; Kevin T Hogan; A Dimitrios Colevas; L Austin Doyle; William D Figg; Domenico Coppola; John D Roberts; Daniel Sullivan; Steven Grant Journal: Clin Cancer Res Date: 2014-09-23 Impact factor: 12.531